Deep learning is expected to aid pathologists by automating tasks such as tumour segmentation. We aimed to develop one universal tumour segmentation model for histopathological images and examine its performance in different cancer types. The model was developed using over 20 000 whole-slide images from over 4 000 patients with colorectal, endometrial, lung, or prostate carcinoma. Performance was validated in pre-planned analyses on external cohorts with over 3 000 patients across six cancer types. Exploratory analyses included over 1 500 additional patients from The Cancer Genome Atlas. Average Dice coefficient was over 80% in all validation cohorts with en bloc resection specimens and in The Cancer Genome Atlas cohorts. No loss of performance was observed when comparing the universal model with models specialised on single cancer types. In conclusion, extensive and rigorous evaluations demonstrate that generic tumour segmentation by a single model is possible across cancer types, patient populations, sample preparations, and slide scanners.

Background: There are many challenges and opportunities in the clinical deployment of AI tools in radiology. The current study describes a radiology software platform called NeoMedSys that can enable efficient deployment and refinements of AI models. We evaluated the feasibility and effectiveness of running NeoMedSys for three months in real-world clinical settings and focused on improvement performance of an in-house developed AI model (VIOLA-AI) designed for intracranial hemorrhage (ICH) detection. Methods: NeoMedSys integrates tools for deploying, testing, and optimizing AI models with a web-based medical image viewer, annotation system, and hospital-wide radiology information systems. A prospective pragmatic investigation was deployed using clinical cases of patients presenting to the largest Emergency Department in Norway (site-1) with suspected traumatic brain injury (TBI) or patients with suspected stroke (site-2). We assessed ICH classification performance as VIOLA-AI encountered new data and underwent pre-planned model retraining. Performance metrics included sensitivity, specificity, accuracy, and the area under the receiver operating characteristic curve (AUC). Results: NeoMedSys facilitated iterative improvements in the AI model, significantly enhancing its diagnostic accuracy. Automated bleed detection and segmentation were reviewed in near real-time to facilitate re-training VIOLA-AI. The iterative refinement process yielded a marked improvement in classification sensitivity, rising to 90.3% (from 79.2%), and specificity that reached 89.3% (from 80.7%). The bleed detection ROC analysis for the entire sample demonstrated a high area-under-the-curve (AUC) of 0.949 (from 0.873). Model refinement stages were associated with notable gains, highlighting the value of real-time radiologist feedback.

Accurate disease risk prediction based on genomic and clinical data can lead to more effective disease screening, early prevention, and personalized treatment strategies. However, despite the identifications of hundreds of disease-associated genomic and molecular features for many disease traits through genome-wide studies in the past two decades, drug resistance often causes the targeted therapies to fail in cancer patients, which is largely due to tumor heterogeneity (Zhang et al., 2022). For advanced cancers, tumor heterogeneity encompasses both the malignant cells and their microenvironment, which makes it challenging to develop accurate prediction models for personalized treatment strategies that account for intratumor heterogeneity. Single-cell technologies provide an unprecedented opportunity for dissecting the interplay between the cancer cells and the associated tumor microenvironment (TME), and the produced high-dimensional omics data should also augment existing survival modeling approaches for identifying tumor cell type-specific genes predictive of cancer patient survival.

Arrhythmia is a common cardiac condition that can precipitate severe complications without timely intervention. While continuous monitoring is essential for timely diagnosis, conventional approaches such as electrocardiogram and wearable devices are constrained by their reliance on specialized medical expertise and patient discomfort from their contact nature. Existing contactless monitoring, primarily designed for healthy subjects, face significant challenges when analyzing reflected signals from arrhythmia patients due to disrupted spatial stability and temporal consistency. In this paper, we introduce mCardiacDx, a radar-driven contactless system that accurately analyzes reflected signals and reconstructs heart pulse waveforms for arrhythmia monitoring and diagnosis. The key contributions of our work include a novel precise target localization (PTL) technique that locates reflected signals despite spatial disruptions, and an encoder-decoder model that transforms these signals into HPWs, addressing temporal inconsistencies. Our evaluation on a large dataset of healthy subjects and arrhythmia patients shows that both mCardiacDx and PTL outperform state-of-the-art approach in arrhythmia monitoring and diagnosis, also demonstrating improved performance in healthy subjects.

Background: Clinical natural language processing (NLP) refers to the use of computational methods for extracting, processing, and analyzing unstructured clinical text data, and holds a huge potential to transform healthcare in various clinical tasks. Objective: The study aims to perform a systematic review to comprehensively assess and analyze the state-of-the-art NLP methods for the mainland Scandinavian clinical text. Method: A literature search was conducted in various online databases including PubMed, ScienceDirect, Google Scholar, ACM digital library, and IEEE Xplore between December 2022 and February 2024. Further, relevant references to the included articles were also used to solidify our search. The final pool includes articles that conducted clinical NLP in the mainland Scandinavian languages and were published in English between 2010 and 2024. Results: Out of the 113 articles, 18% (n=21) focus on Norwegian clinical text, 64% (n=72) on Swedish, 10% (n=11) on Danish, and 8% (n=9) focus on more than one language. Generally, the review identified positive developments across the region despite some observable gaps and disparities between the languages. There are substantial disparities in the level of adoption of transformer-based models. In essential tasks such as de-identification, there is significantly less research activity focusing on Norwegian and Danish compared to Swedish text. Further, the review identified a low level of sharing resources such as data, experimentation code, pre-trained models, and rate of adaptation and transfer learning in the region. Conclusion: The review presented a comprehensive assessment of the state-of-the-art Clinical NLP for electronic health records (EHR) text in mainland Scandinavian languages and, highlighted the potential barriers and challenges that hinder the rapid advancement of the field in the region.

Artificial intelligence could have the capability to pinpoint cancer diagnoses a lot sooner. A new study published in the journal Radiology last week noted that AI helped predict one-third of breast cancer cases up to two years prior to diagnosis. The research surveyed imaging data and screening information from BreastScreen Norway exams performed from January 2004 to December 2019. Women who were later diagnosed with breast cancer based on these exams were given an AI risk score by a "commercially available AI system," according to the study's findings. The scores were ranked 1-7 for low-risk malignancy, 8-9 for intermediate risk and 10 for high-risk malignancy.

State-of-the-art automatic sleep staging methods have already demonstrated comparable reliability and superior time efficiency to manual sleep staging. However, fully automatic black-box solutions are difficult to adapt into clinical workflow and the interaction between explainable automatic methods and the work of sleep technologists remains underexplored and inadequately conceptualized. Thus, we propose a human-in-the-loop concept for sleep analysis, presenting an automatic sleep staging model (aSAGA), that performs effectively with both clinical polysomnographic recordings and home sleep studies. To validate the model, extensive testing was conducted, employing a preclinical validation approach with three retrospective datasets; open-access, clinical, and research-driven. Furthermore, we validate the utilization of uncertainty mapping to identify ambiguous regions, conceptualized as gray areas, in automatic sleep analysis that warrants manual re-evaluation. The results demonstrate that the automatic sleep analysis achieved a comparable level of agreement with manual analysis across different sleep recording types. Moreover, validation of the gray area concept revealed its potential to enhance sleep staging accuracy and identify areas in the recordings where sleep technologists struggle to reach a consensus. In conclusion, this study introduces and validates a concept from explainable artificial intelligence into sleep medicine and provides the basis for integrating human-in-the-loop automatic sleep staging into clinical workflows, aiming to reduce black-box criticism and the burden associated with manual sleep staging.

AZoRobotics speaks with Alice Ruixue Ai from the University of Oslo about her efforts to create an artificial intelligence (AI)-based virtual screening algorithm and a cross-species Alzheimer's disease (AD) drug verification system. This system could help provide a fast, cost-effective and highly accurate method for the identification of potent mitophagy inducers to maintain brain health. Alzheimer's Disease (AD) is the most common form of dementia, seen mainly in the elderly. Around 50 million people in the world suffer from dementia, and about 70% of those people have AD, so this is a huge problem for society. It is estimated that managing the health and social costs for people with AD will cost about 2 trillion dollars by the year 2030.

We present a novel benchmark and associated evaluation metrics for assessing the performance of text anonymization methods. Text anonymization, defined as the task of editing a text document to prevent the disclosure of personal information, currently suffers from a shortage of privacy-oriented annotated text resources, making it difficult to properly evaluate the level of privacy protection offered by various anonymization methods. This paper presents TAB (Text Anonymization Benchmark), a new, open-source annotated corpus developed to address this shortage. The corpus comprises 1,268 English-language court cases from the European Court of Human Rights (ECHR) enriched with comprehensive annotations about the personal information appearing in each document, including their semantic category, identifier type, confidential attributes, and co-reference relations. Compared to previous work, the TAB corpus is designed to go beyond traditional de-identification (which is limited to the detection of predefined semantic categories), and explicitly marks which text spans ought to be masked in order to conceal the identity of the person to be protected. Along with presenting the corpus and its annotation layers, we also propose a set of evaluation metrics that are specifically tailored towards measuring the performance of text anonymization, both in terms of privacy protection and utility preservation. We illustrate the use of the benchmark and the proposed metrics by assessing the empirical performance of several baseline text anonymization models. The full corpus along with its privacy-oriented annotation guidelines, evaluation scripts and baseline models are available on: https://github.com/NorskRegnesentral/text-anonymisation-benchmark

Artificial intelligence and the cell's self-cleansing system are the keys behind the novel medication. The treatment may strengthen other organs as well. One in six Norwegians over 80 is affected by Alzheimer's disease. Numbers are even higher worldwide, and there is still no cure available. Researchers at the faculty have developed an artificial intelligence (AI) method to help them identify potential new medicines for Alzheimer's.